The booming U.S. egg donation industry requires more regulation to safeguard donor welfare.
In regulating AI in medicine, FDA should exercise care in implementing a principles-based framework.
The structure of some essential oils companies makes it harder for federal agencies to restrain false claims.
Scholar claims that regulatory sandboxes such as emergency use authorizations boost innovation, but at a cost.
FDA warns consumers to protect themselves from a known carcinogen in hair smoothing products.
Scholars examine the effectiveness of the contentious 340B Drug Pricing Program.
COVID-19 highlights a blood donation deferral policy that clashes with modern science.
Government watchdog finds that FDA is not properly inspecting imported seafood.
Lawyer proposes a new legal framework for reviewing FDA’s refusal to regulate lethal injection drugs.
Scholar explains why the DEA—not FDA—has power over the classification of potentially addictive substances.
FDA faces mounting pressure from advocacy groups claiming a high chemical content in macaroni and cheese.
Scholars reflect on the need for stronger regulatory oversight of cosmetics in the United States.